CELECOR THERAPEUTICS
CeleCor Therapeutics develops a RUC-4 novel small molecule inhibitor designed to be the first point of contact treatment for segment elevated myocardial infarction. The molecule inhibitor uses a thrombolytic agent for percutaneous coronary intervention that can be administered subcutaneously by auto-injector, enabling decreased mortality and later development of heart failure.
CELECOR THERAPEUTICS
Industry:
Biotechnology Medical Therapeutics
Founded:
2017-01-01
Address:
Del Mar, California, United States
Country:
United States
Website Url:
http://www.celecor.com
Status:
Active
Contact:
+1 858 777 9750
Total Funding:
3.7 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apache Amazon Google Apps For Business Amazon Virginia Region
Similar Organizations
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.celecor.com
- Host name: ec2-54-201-159-125.us-west-2.compute.amazonaws.com
- IP address: 54.201.159.125
- Location: Boardman United States
- Latitude: 45.8491
- Longitude: -119.7143
- Metro Code: 810
- Timezone: America/Los_Angeles
- Postal: 97818
More informations about "CeleCor Therapeutics"
About Us - CeleCor Therapeutics
We founded CeleCor Therapeutics to improve the treatment of ST-segment elevation myocardial infarctions (STEMI heart attacks) at the first point of medical contact.See details»
CeleCor Therapeutics - Crunchbase Company Profile
CeleCor Therapeutics develops first-point contact treatments for segment elevated myocardial infarction.See details»
CeleCor Therapeutics - Org Chart, Teams, Culture & Jobs | The Org
View CeleCor Therapeutics' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
CeleCor Therapeutics Information - RocketReach
CeleCor Therapeutics is a Biotechnology Research, Business Services General, and Business Services company located in Del Mar, California with $3 million in revenue and 5 employees. …See details»
CeleCor Therapeutics - VentureRadar
"CeleCor Therapeutics was founded to develop zalanfiban (RUC-4) , a novel small molecule platelet inhibitor of the platelet GPIIb/IIIa (aIIbß3) receptor, designed for single dose …See details»
Celecor Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Celecor Therapeutics, Inc. of Del Mar, CA. Get the latest business insights from Dun & Bradstreet.See details»
Organization | CeleCor Therapeutics - Purdue University
CeleCor Therapeutics Report issue For profit Phase 2 Founded: San Diego CA United States (2017) Organization Overview First Clinical TrialSee details»
CeleCor Therapeutics 2025 Company Profile: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for CeleCor Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Home - CeleCor Therapeutics
About Us Each year, 800,000 people in the United States have an acute myocardial infarction (AMI), or heart attack. We founded CeleCor Therapeutics to improve the treatment of ST …See details»
CeleCor Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Explore CeleCor Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 3 clinical trials, 1 news, Technology Platform:Small molecule drug ...See details»
CeleCor Therapeutics Management Team | Org Chart - RocketReach
CeleCor Therapeutics employs 7 employees. The CeleCor Therapeutics management team includes Robert Hillman (President and CEO), Mark Nedelman (Acting Site Director), and …See details»
CeleCor Therapeutics - Funding, Financials, Valuation & Investors
CeleCor Therapeutics develops first-point contact treatments for segment elevated myocardial infarction.See details»
52 - CeleCor
We founded CeleCor Therapeutics to improve the treatment of ST-Segment Elevated Myocardial Infarctions (STEMI heart attacks) at the first point of medical contact.See details»
CeleCor Therapeutics - Leadership Team | The Org
About The Leadership Team at CeleCor Therapeutics is responsible for setting the strategic direction of the company, overseeing the development and commercialization of their novel …See details»
CeleCor Therapeutics - Contacts, Employees, Board Members, …
CeleCor Therapeutics has 3 current employee profiles, including Co-Founder Barry Coller. CeleCor Therapeutics has 1 board member or advisor, Andreas Ritzi.See details»
News - CeleCor Therapeutics
May 27, 2025 CeleCor Therapeutics has completed its multinational Phase 3 clinical trial of Disaggpro TM (zalunfiban), an investigational heart-attack drug designed for rapid use at first …See details»
Clinical Development - CeleCor Therapeutics
CeleCor designs a randomized, placebo-controlled clinical trial to study Disaggpro or placebo, subcutaneously injected in STEMI patients treated in ambulances at the first point of contact. …See details»
CeleCor Completes Phase 3 Trial Of Fast-Acting Heart Attack Drug ...
May 29, 2025 May 27, 2025 — CeleCor Therapeutics has successfully completed a Phase 3 clinical trial of its investigational heart attack drug, DisaggproT (zalunfiban), marking a …See details»
CELECOR COMPLETES MULTINATIONAL PHASE 3 …
DEL MAR, Calif., May 27, 2025 /PRNewswire/ -- CeleCor Therapeutics has completed its multinational Phase 3 clinical trial of Disaggpro™ (zalunfiban), an investigational heart-attack …See details»
Celecor Completes Multinational Phase 3 Registrational Study of …
May 27, 2025 CeleBrate tested drug designed for rapid treatment at first point of medical contact CeleCor Therapeutics has completed its multinational Phase 3 clinical trial of DisaggproTM …See details»